Skip to main content

Table 5 Relationship between patient satisfaction and disease- and treatment-related information received

From: Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain

 

n

 

Effectiveness

Adverse events

Cost

Convenience

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Mean (SD)

Before starting the treatment, did your doctor speak to you about the disease?

 Yes, at length

112

76.34 (17.6)

69.91 (36.35)

40.0 (25.86)

86.74 (13.10)

79.63 (15.12)

 Yes, a little

14

62.50 (17.84)

77.86 (31.85)

33.2 (25.91)

82.50 (8.03)

72.14 (15.65)

 p value1)

 

0.002

0.446

0.272

0.050

0.108

Did your doctor speak to you about the different possible treatments for your disease?

 Yes, at length

100

76.70 (17.56)

70.40 (36.57)

40.45 (26.45)

87.70 (12.50)

78.85 (15.73)

 Yes, a little

25

69.40 (17.52)

68.80 (36.15)

35.20 (23.07)

80.00 (11.99)

77.72 (16.20)

 p value1

 

0.012

0.959

0.577

0.007

0.491

Did your doctor speak to you about the characteristics of GRAZAX®?

 Yes, at length

105

76.33 (18.00)

68.62 (37.65)

39.38 (26.47)

87.57 (12.39)

78.84 (15.95)

 Yes, a little

20

69.50 (15.30)

77.75 (28.07)

39.50 (22.59)

78.75 (12.23)

77.50 (15.09)

 p value1

 

0.023

0.904

0.460

0.008

0.237

  1. 1The p value was calculated using the bilateral ANOVA parametric test (or nonparametric Kruskal–Wallis) with a 95% confidence level